ELISA News and Research

RSS

Study shows difference in antibody levels in response to SARS-CoV-2 infection and type of vaccination

In a recent study, researchers aimed to monitor the levels of the anti-SARS-CoV-2 spike IgG levels in populations that were subjected to routine tests.

24 Aug 2021

COVID booster shots might be needed in subgroup of HIV-positive individuals

The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic destroying lives and economies. COVID-19 is not curable, so vaccines are the only safeguard during this pandemic.

23 Aug 2021

Nanotechnology provides novel solutions against zoonotic viruses

Therefore, scientists functionalize nanoparticles to act against these pathogenic viruses in a clinical strategy. In a recent review published in the journal Microbial Pathogenesis, researchers look at the novel solutions against zoonotic viruses provided by nanotechnology.

23 Aug 2021

A combination of oral bacteria and intranasal vaccine provide protection from influenza A virus and COVID-19

A new study published in the journal mBio focuses on the role of nasal bacteria in eliciting virus-specific adaptive immunity.

20 Aug 2021

Small study suggests a mix-and-match COVID-19 booster produces robust antibody levels

In a small study published in the medRxiv* preprint server, people given a booster Johnson & Johnson COVID-19 shot showed elevated and robust antibody levels.

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047.

From Sino Biological Inc. 17 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variants

In a recent bioRxiv* preprint research paper, a large group of US scientists demonstrate how a booster dose of the mRNA-1273 vaccine can substantially improve both the potency and range of neutralizing antibody responses and mediate protection against upper and lower airway infection by a range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern – even those relatively resistant to in vitro neutralization.

16 Aug 2021

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

Evaluation of mRNA vaccine responses with a surrogate SARS-CoV-2 viral neutralization assay

In the current study, the authors evaluate several different competitive ELISAs that could be used to measure serum antibodies.

11 Aug 2021

Activation of NLRP3 inflammasome by the N protein of SARS-CoV-2 to induce hyperinflammation

A new study has revealed the mechanism by which the SARS-CoV-2 N protein activates NLRP3 inflammasomes to induce hyperinflammation.

5 Aug 2021

COVID vaccines generate antibodies in saliva

Researchers in the United States and Canada have conducted a study showing that the vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) generate local antibody responses in the salivary gland that are independent of the systemic immune response.

5 Aug 2021

ELISA News and Research

Study shows difference in antibody levels in response to SARS-CoV-2 infection and type of vaccination

COVID booster shots might be needed in subgroup of HIV-positive individuals

Nanotechnology provides novel solutions against zoonotic viruses

A combination of oral bacteria and intranasal vaccine provide protection from influenza A virus and COVID-19

Small study suggests a mix-and-match COVID-19 booster produces robust antibody levels

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange

How delta and kappa variants of SARS-CoV-2 evade the immune system

Primate study shows benefit of mRNA vaccine booster shot against SARS-CoV-2 variants

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

Evaluation of mRNA vaccine responses with a surrogate SARS-CoV-2 viral neutralization assay

Activation of NLRP3 inflammasome by the N protein of SARS-CoV-2 to induce hyperinflammation

COVID vaccines generate antibodies in saliva

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Monoclonal antibody could inform development of pan-coronavirus vaccines

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News